Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
04-13 Argent BioPharma Limited completed the acquisition of 48% stake in Cannpal Animal Therapeutics Limited from AusCann Group Holdings Ltd. CI
10/03/23 Layton Mills and Margaret Curtis agreed to acquire 52% stake in CannPal Animal Therapeutics Limited from AusCann Group Holdings Ltd for AUD1. CI
11/03/21 AusCann Group Holdings Ltd completed the acquisition of CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others. CI
19/02/21 Cannpal Animal Therapeutics : Narrows Fiscal H1 Loss on Higher Revenue MT
19/02/21 Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2020 CI
08/01/21 AusCann : CannPal Managing Director to Lead Merged Company Formed With AusCann; CannPal Rises 11% MT
16/11/20 AusCann Group Holdings Ltd entered into a scheme implementation deed to acquire CannPal Animal Therapeutics Limited from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others for AUD 16.9 million. CI
28/08/20 CannPal Animal Therapeutics Limited Announces Resignation of Max Johnston as Non-Executive Director CI
21/07/20 CannPal Animal Therapeutics Limited Announces Completion of its Safety and Efficacy Study for DermaCann CI
11/03/20 CannPal Animal Therapeutics Limited Announces FDA Establishes Investigational New Animal Drug file for CPAT-01 CI
26/02/20 Cannpal Animal Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2019 CI
06/01/20 CannPal Animal Therapeutics Limited Enters into Exclusive Licensing Agreement with Commonwealth Scientific and Industrial Research Organisation CI
25/10/19 49,365,405 Ordinary Shares of Cannpal Animal Therapeutics Limited are subject to a Lock-Up Agreement Ending on 25-OCT-2019. CI
Manager TitleAgeSince
Chief Executive Officer - 03/06/2016
Director of Finance/CFO - 01/10/2016
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 03/06/2016
Chairman - 07/07/2017
Director/Board Member - 01/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+6.25%+13.33% - - 12.26M
+2.14%+7.57%+74.46%+123.84% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+0.82%+1.68%-11.66%-15.06% 22.81B
+2.90%+6.24%-3.73%+408.44% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+9.80%+26.27%-34.74% 15.56B
+0.58%-0.96%+18.98%+159.82% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
Average +1.80%+1.74%+39.24%+120.83% 24.16B
Weighted average by Cap. +1.25%+3.17%+45.86%+113.67%
Logo CannPal Animal Therapeutics Limited
CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!